7,978 Shares in Incyte Co. (NASDAQ:INCY) Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. acquired a new stake in Incyte Co. (NASDAQ:INCY) during the 4th quarter, HoldingsChannel reports. The firm acquired 7,978 shares of the biopharmaceutical company’s stock, valued at approximately $551,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in INCY. Point72 Asset Management L.P. purchased a new stake in shares of Incyte during the third quarter worth $156,611,000. Charles Schwab Investment Management Inc. raised its stake in shares of Incyte by 2.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,643,067 shares of the biopharmaceutical company’s stock worth $113,487,000 after purchasing an additional 33,847 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Incyte by 7.5% during the 4th quarter. Bank of New York Mellon Corp now owns 1,127,515 shares of the biopharmaceutical company’s stock valued at $77,877,000 after buying an additional 78,827 shares during the last quarter. Candriam S.C.A. grew its stake in shares of Incyte by 27.8% in the 4th quarter. Candriam S.C.A. now owns 1,034,652 shares of the biopharmaceutical company’s stock valued at $71,463,000 after buying an additional 224,919 shares in the last quarter. Finally, Barclays PLC raised its position in Incyte by 8.1% during the third quarter. Barclays PLC now owns 1,031,932 shares of the biopharmaceutical company’s stock valued at $68,208,000 after acquiring an additional 77,542 shares in the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Insider Transactions at Incyte

In related news, EVP Sheila A. Denton sold 14,069 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $74.07, for a total value of $1,042,090.83. Following the completion of the transaction, the executive vice president now owns 25,848 shares of the company’s stock, valued at $1,914,561.36. This represents a 35.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $67.69, for a total value of $1,340,735.83. Following the sale, the executive vice president now directly owns 33,567 shares in the company, valued at $2,272,150.23. The trade was a 37.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 46,827 shares of company stock valued at $3,322,618. Company insiders own 17.60% of the company’s stock.

Incyte Price Performance

Shares of INCY stock opened at $62.78 on Tuesday. Incyte Co. has a 12 month low of $50.35 and a 12 month high of $83.95. The company has a market capitalization of $12.15 billion, a P/E ratio of 232.53, a P/E/G ratio of 0.41 and a beta of 0.76. The stock has a 50 day moving average of $70.42 and a two-hundred day moving average of $70.17. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last issued its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. As a group, equities analysts expect that Incyte Co. will post 4.86 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Stifel Nicolaus boosted their target price on shares of Incyte from $75.00 to $77.00 and gave the stock a “hold” rating in a research report on Monday, February 10th. Truist Financial cut their target price on Incyte from $74.00 to $72.00 and set a “hold” rating on the stock in a report on Tuesday, March 18th. Citigroup decreased their price target on Incyte from $97.00 to $88.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. Guggenheim downgraded Incyte from a “buy” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research note on Tuesday, March 18th. Finally, Royal Bank of Canada lowered their price target on Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $74.88.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.